178 related articles for article (PubMed ID: 32934722)
21. Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: Final results of 2 parallel phase 2 clinical trials.
Kong L; Zhang Y; Hu C; Guo Y; Lu JJ
Cancer; 2017 Jun; 123(12):2258-2267. PubMed ID: 28192641
[TBL] [Abstract][Full Text] [Related]
22. Prognostics of Cyclin-D1 expression with chemoradiation response in patients of locally advanced oral squamous cell carcinoma.
Khan H; Gupta S; Husain N; Misra S; Singh N; Negi MP
J Cancer Res Ther; 2014; 10(2):258-64. PubMed ID: 25022375
[TBL] [Abstract][Full Text] [Related]
23. Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis.
Liu GY; Lv X; Wu YS; Mao MJ; Ye YF; Yu YH; Liang H; Yang J; Ke LR; Qiu WZ; Huang XJ; Li WZ; Guo X; Xiang YQ; Xia WX
Cancer Commun (Lond); 2018 May; 38(1):21. PubMed ID: 29764487
[TBL] [Abstract][Full Text] [Related]
24. Randomized Controlled Study Comparing Efficacy and Toxicity of Weekly vs. 3-Weekly Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma.
Tousif D; Sarathy V; Kumar R; Naik R
Front Oncol; 2020; 10():1284. PubMed ID: 32850394
[No Abstract] [Full Text] [Related]
25. Prognostic Role of Circulating Tumor Cells during Induction Chemotherapy Followed by Curative Surgery Combined with Postoperative Radiotherapy in Patients with Locally Advanced Oral and Oropharyngeal Squamous Cell Cancer.
Inhestern J; Oertel K; Stemmann V; Schmalenberg H; Dietz A; Rotter N; Veit J; Görner M; Sudhoff H; Junghanß C; Wittekindt C; Pachmann K; Guntinas-Lichius O
PLoS One; 2015; 10(7):e0132901. PubMed ID: 26186556
[TBL] [Abstract][Full Text] [Related]
26. Microarray gene expression analysis of chemosensitivity for docetaxel, cisplatin and 5-fluorouracil (TPF) combined chemotherapeutic regimen in hypopharyngeal squamous cell carcinoma.
Lian M; Wang H; Fang J; Zhai J; Wang R; Shen X; Yang Y; Ma Z; Liu H
Chin J Cancer Res; 2017 Jun; 29(3):204-212. PubMed ID: 28729771
[TBL] [Abstract][Full Text] [Related]
27. Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation.
Posner MR; Norris CM; Wirth LJ; Shin DM; Cullen KJ; Winquist EW; Blajman CR; Mickiewicz EA; Frenette GP; Plinar LF; Cohen RB; Steinbrenner LM; Freue JM; Gorbunova VA; Tjulandin SA; Raez LE; Adkins DR; Tishler RB; Roessner MR; Haddad RI;
Ann Oncol; 2009 May; 20(5):921-7. PubMed ID: 19179556
[TBL] [Abstract][Full Text] [Related]
28. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial.
Sun Y; Li WF; Chen NY; Zhang N; Hu GQ; Xie FY; Sun Y; Chen XZ; Li JG; Zhu XD; Hu CS; Xu XY; Chen YY; Hu WH; Guo L; Mo HY; Chen L; Mao YP; Sun R; Ai P; Liang SB; Long GX; Zheng BM; Feng XL; Gong XC; Li L; Shen CY; Xu JY; Guo Y; Chen YM; Zhang F; Lin L; Tang LL; Liu MZ; Ma J
Lancet Oncol; 2016 Nov; 17(11):1509-1520. PubMed ID: 27686945
[TBL] [Abstract][Full Text] [Related]
29. Osteopontin Involves Cisplatin Resistance and Poor Prognosis in Oral Squamous Cell Carcinoma.
Luo SD; Chen YJ; Liu CT; Rau KM; Chen YC; Tsai HT; Chen CH; Chiu TJ
Biomed Res Int; 2015; 2015():508587. PubMed ID: 26491674
[TBL] [Abstract][Full Text] [Related]
30. STAT3- and GSK3β-mediated Mcl-1 regulation modulates TPF resistance in oral squamous cell carcinoma.
Maji S; Shriwas O; Samal SK; Priyadarshini M; Rath R; Panda S; Das Majumdar SK; Muduly DK; Dash R
Carcinogenesis; 2019 Mar; 40(1):173-183. PubMed ID: 30395230
[TBL] [Abstract][Full Text] [Related]
31. International randomized phase 2 study on the addition of docetaxel to the combination of cisplatin and 5-fluorouracil in the induction treatment for nasopharyngeal carcinoma in children and adolescents.
Casanova M; Özyar E; Patte C; Orbach D; Ferrari A; Veyrat-Follet C; Errihani H; Pan J; Zhang L; Shen L; Grzegorzewski KJ; Varan A
Cancer Chemother Pharmacol; 2016 Feb; 77(2):289-98. PubMed ID: 26666649
[TBL] [Abstract][Full Text] [Related]
32. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Posner MR; Hershock DM; Blajman CR; Mickiewicz E; Winquist E; Gorbounova V; Tjulandin S; Shin DM; Cullen K; Ervin TJ; Murphy BA; Raez LE; Cohen RB; Spaulding M; Tishler RB; Roth B; Viroglio Rdel C; Venkatesan V; Romanov I; Agarwala S; Harter KW; Dugan M; Cmelak A; Markoe AM; Read PW; Steinbrenner L; Colevas AD; Norris CM; Haddad RI;
N Engl J Med; 2007 Oct; 357(17):1705-15. PubMed ID: 17960013
[TBL] [Abstract][Full Text] [Related]
33. Understanding molecular markers in recurrent oral squamous cell carcinoma treated with chemoradiation.
Gupta S; Kushwaha VS; Verma S; Khan H; Bhatt ML; Husain N; Negi MP; Bhosale VV; Ghatak A
Heliyon; 2016 Dec; 2(12):e00206. PubMed ID: 27981249
[TBL] [Abstract][Full Text] [Related]
34. Comparison of induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by radiation vs concurrent chemoradiotherapy with TPF in patients with locally advanced squamous cell carcinoma of the head and neck.
Katori H; Tsukuda M
Clin Oncol (R Coll Radiol); 2005 May; 17(3):148-52. PubMed ID: 15900997
[TBL] [Abstract][Full Text] [Related]
35. Daxx and TCF4 interaction links to oral squamous cell carcinoma growth by promoting cell cycle progression via induction of cyclin D1 expression.
Lin GJ; Huang YS; Lin CK; Huang SH; Shih HM; Sytwu HK; Chen YW
Clin Oral Investig; 2016 Apr; 20(3):533-40. PubMed ID: 26205068
[TBL] [Abstract][Full Text] [Related]
36. Cisplatin and Fluorouracil Induction Chemotherapy With or Without Docetaxel in Locoregionally Advanced Nasopharyngeal Carcinoma.
Jin T; Qin WF; Jiang F; Jin QF; Wei QC; Jia YS; Sun XN; Li WF; Chen XZ
Transl Oncol; 2019 Apr; 12(4):633-639. PubMed ID: 30797141
[TBL] [Abstract][Full Text] [Related]
37. In vivo gene expression profiling for chemosensitivity to docetaxel-cisplatin-5-FU (TPF) triplet regimen in laryngeal squamous cell carcinoma and the effect of TPF treatment on related gene expression in vitro.
Lian M; Shi Q; Fang J; Feng L; Ma H; Wang H; Zhang L; Wang H; Ma Z; Liu H
Acta Otolaryngol; 2017 Jul; 137(7):765-772. PubMed ID: 28125325
[TBL] [Abstract][Full Text] [Related]
38. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Haddad R; O'Neill A; Rabinowits G; Tishler R; Khuri F; Adkins D; Clark J; Sarlis N; Lorch J; Beitler JJ; Limaye S; Riley S; Posner M
Lancet Oncol; 2013 Mar; 14(3):257-64. PubMed ID: 23414589
[TBL] [Abstract][Full Text] [Related]
39. Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil-cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck.
Pignon JP; Syz N; Posner M; Olivares R; Le Lann L; Yver A; Dunant A; Lewin F; Dalley DN; Paccagnella A; Taylor SG; Domenge C; Bourhis J; Mazumdar M
Anticancer Drugs; 2004 Apr; 15(4):331-40. PubMed ID: 15057136
[TBL] [Abstract][Full Text] [Related]
40. Up-regulation of survivin in oral squamous cell carcinoma correlates with poor prognosis and chemoresistance.
Su L; Wang Y; Xiao M; Lin Y; Yu L
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Oct; 110(4):484-91. PubMed ID: 20868995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
